Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors

Utility of voriconazole therapeutic drug monitoring: a meta-analysis

(2016) Me-Linh Luong et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress

(2016) Thomas Colatsky et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Prescribers' Practice of Assessing Arrhythmia Risk with QT-Prolonging Medications

(2014) Wai Kah Choo et al.   Cardiovascular Therapeutics

Phototoxicity, Pseudoporphyria, and Photo-onycholysis Due to Voriconazole in a Pediatric Patient With Leukemia and Invasive Aspergillosis

(2014) Z. I. Willis et al.   Journal of the Pediatric Infectious Diseases Society

Effect of Combined Fluoroquinolone and Azole Use on QT Prolongation in Hematology Patients

(2012) John D. Zeuli et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug-induced arrhythmia: pharmacogenomic prescribing?

(2012) E. R. Behr et al.   EUROPEAN HEART JOURNAL

Voriconazole-induced QT interval prolongation and torsades de pointes

(2011) Ebru Aypar et al.   PEDIATRICS INTERNATIONAL

Fluconazole inhibits hERG K+ channel by direct block and disruption of protein trafficking

(2010) Shengna Han et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

Collation, assessment and analysis of literaturein vitrodata on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties

(2008) Sebastian Polak et al.   JOURNAL OF APPLIED TOXICOLOGY